-+ 0.00%
-+ 0.00%
-+ 0.00%
PRELUDE THERAPEUTICS ANNOUNCES ACCEPTANCE OF PRECLINICAL ABSTRACT FOR PRT13722, A FIRST-IN-CLASS ORAL KAT6A SELECTIVE DEGRADER AT THE 2026 AACR ANNUAL MEETING
Share

Please log in to view news

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending